A Phase 1, Randomized, Double-Blind, Single-Dose, Placebo-Controlled Safety, Tolerability, And Pharmacokinetic/Pharmacodynamic Study Of Evolocumab In Healthy Chinese Subjects

PURPOSE: Evolocumab is a human monoclonal antibody that reduces circulating low-density lipoprotein cholesterol (LDL-C) by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9). Data on evolocumab pharmacokinetics and pharmacodynamics are derived mostly from Caucasian populations. The obj...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Chao, Lu, Hong, Yuan, Fei, Chen, Wei-Li, Xu, Hong-Rong, Li, Hui, Hsu, Cheng-Pang, Egbuna, Ogo, Wu, Jihua, Dias, Clapton, Abosaleem, Bassam, Rana, Jitesh, Monsalvo, Maria Laura, Li, Xue-Ning, Yu, Zhigang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816231/
https://www.ncbi.nlm.nih.gov/pubmed/31695519
http://dx.doi.org/10.2147/CPAA.S208033

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816231/
https://www.ncbi.nlm.nih.gov/pubmed/31695519
http://dx.doi.org/10.2147/CPAA.S208033

Ejemplares similares